Amedeo Smart

Free Medical Literature Service



Breast Cancer

  Free Subscription


2 AJR Am J Roentgenol
1 Am J Epidemiol
3 Ann Surg Oncol
1 BMC Cancer
2 Br J Cancer
4 Breast Cancer
1 Breast Cancer (Dove Med Press)
3 Breast Cancer Res
5 Breast Cancer Res Treat
1 Cancer Cell
2 Cancer Lett
1 Cancer Res
2 Clin Breast Cancer
1 Clin Exp Metastasis
1 Curr Treat Options Oncol
1 Exp Cell Res
2 Gene
1 Int J Radiat Oncol Biol Phys
1 J Clin Invest
1 J Clin Oncol
2 J Natl Cancer Inst
2 Lancet
1 Lancet Oncol
1 Mol Ther Oncol
1 N Engl J Med
1 Nature
1 NPJ Breast Cancer
1 Oncogene
2 PLoS One
1 Radiol Artif Intell
2 Radiol Imaging Cancer
2 Radiology
1 Semin Oncol

    AJR Am J Roentgenol

  1. JIRARAYAPONG J, Portnow LH, Chikarmane SA, Lan Z, et al
    High Peritumoral and Intratumoral T2 Signal Intensity in HER2+ Breast Cancers on Preneoadjuvant Breast MRI: Assessment of Associations With Histopathologic Characteristics.
    AJR Am J Roentgenol. 2023 Dec 20. doi: 10.2214/AJR.23.30280.
    >> Share

  2. NGUYEN DL, Greenwood HI, Rahbar H, Grimm LJ, et al
    Evolving Treatment Paradigms for Low-Risk Ductal Carcinoma In Situ: Imaging Needs.
    AJR Am J Roentgenol. 2023 Dec 13. doi: 10.2214/AJR.23.30503.
    >> Share

    Am J Epidemiol

  3. PAPANTONIOU K, Hansen J
    Cohort Studies Versus Case-Control Studies on Night-Shift Work and Cancer Risk: The Importance of Exposure Assessment.
    Am J Epidemiol. 2024;193:577-579.
    >> Share

    Ann Surg Oncol

  4. CHU JJ, Tadros AB, Vingan PS, Assel MJ, et al
    Remote Symptom Monitoring with Clinical Alerts Following Mastectomy: Do Early Symptoms Predict 30-Day Surgical Complications.
    Ann Surg Oncol. 2024;31:3377-3386.
    >> Share

  5. GREENE AJE, Davis J, Moon J, Dubin I, et al
    Determination of Factors Associated with Upstage in Atypical Ductal Hyperplasia to Identify Low-Risk Patients Where Active Surveillance May be an Alternative.
    Ann Surg Oncol. 2024;31:3177-3185.
    >> Share

  6. XIONG M, Young AT, Fernandez A, Jones JS, et al
    Understanding Breast Cancer Surgery Through Tiktok: an Analysis of Video Content and Viewer Engagement.
    Ann Surg Oncol. 2024 Apr 9. doi: 10.1245/s10434-024-15268.
    >> Share

    BMC Cancer

  7. LIU Z, Li J, Zhao F, Ren D, et al
    Long-term survival after neoadjuvant therapy for triple-negative breast cancer under different treatment regimens: a systematic review and network meta-analysis.
    BMC Cancer. 2024;24:440.
    >> Share

    Br J Cancer

  8. ALEXANDER J, Schipper K, Nash S, Brough R, et al
    Pathway-based signatures predict patient outcome, chemotherapy benefit and synthetic lethal dependencies in invasive lobular breast cancer.
    Br J Cancer. 2024 Apr 10. doi: 10.1038/s41416-024-02679.
    >> Share

  9. ARSHAD M, Azad A, Chan PYK, Vigneswara V, et al
    Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models.
    Br J Cancer. 2024 Apr 10. doi: 10.1038/s41416-024-02665.
    >> Share

    Breast Cancer

  10. TOKUDA PJK, Mitsuyoshi T, Ono Y, Kishi T, et al
    Acute adverse events of ultra-hypofractionated whole-breast irradiation after breast-conserving surgery for early breast cancer in Japan: an interim analysis of the multi-institutional phase II UPBEAT study.
    Breast Cancer. 2024 Apr 12. doi: 10.1007/s12282-024-01577.
    >> Share

  11. DE MOURA A, Loirat D, Vaillant S, Korbi S, et al
    Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases.
    Breast Cancer. 2024 Apr 10. doi: 10.1007/s12282-024-01565.
    >> Share

  12. SUZUKI K, Morishita S, Nakano J, Okayama T, et al
    Association between quality of life and mortality risk in patients with breast cancer: a systematic review and meta-analysis.
    Breast Cancer. 2024 Apr 9. doi: 10.1007/s12282-024-01581.
    >> Share

  13. WATANABE A, Tsunashima R, Kato C, Kitano S, et al
    Investigation of recurrence prediction ability of EndoPredict((R)) using microarray data from fresh frozen tissues in ER-positive, HER2-negative breast cancer and indication expansion of EndoPredict((R)) from microarray data from fresh-frozen to FFPE
    Breast Cancer. 2024 Apr 8. doi: 10.1007/s12282-024-01573.
    >> Share

    Breast Cancer (Dove Med Press)

  14. WANG S, Chen Y, Li W, Hao C, et al
    Serum HER2 Level Predicts Therapeutic Efficacy and Prognosis in Advanced Breast Cancer Patients.
    Breast Cancer (Dove Med Press). 2024;16:163-179.
    >> Share

    Breast Cancer Res

  15. KARIHTALA P, Leivonen SK, Puistola U, Urpilainen E, et al
    Serum protein profiling reveals an inflammation signature as a predictor of early breast cancer survival.
    Breast Cancer Res. 2024;26:61.
    >> Share

  16. ZHANG W, Song X, Jin Z, Zhang Y, et al
    U2AF2-SNORA68 promotes triple-negative breast cancer stemness through the translocation of RPL23 from nucleoplasm to nucleolus and c-Myc expression.
    Breast Cancer Res. 2024;26:60.
    >> Share

  17. WOOLPERT KM, Schmidt JA, Ahern TP, Hjorth CF, et al
    Clinical factors associated with patterns of endocrine therapy adherence in premenopausal breast cancer patients.
    Breast Cancer Res. 2024;26:59.
    >> Share

    Breast Cancer Res Treat

  18. ALLSOPP RC, Guo Q, Page K, Bhagani S, et al
    Circulating tumour DNA dynamics during alternating chemotherapy and hormonal therapy in metastatic breast cancer: the ALERT study.
    Breast Cancer Res Treat. 2024 Apr 6. doi: 10.1007/s10549-024-07316.
    >> Share

  19. RUKHSANA, Supty AT, Hussain M, Lee Y, et al
    STK3 higher expression association with clinical characteristics in intrinsic subtypes of breast cancer invasive ductal carcinoma patients.
    Breast Cancer Res Treat. 2024 Apr 9. doi: 10.1007/s10549-024-07248.
    >> Share

  20. WANG Y, Sun W, Karlsson E, Kang Lovgren S, et al
    Clinical evaluation of deep learning-based risk profiling in breast cancer histopathology and comparison to an established multigene assay.
    Breast Cancer Res Treat. 2024 Apr 9. doi: 10.1007/s10549-024-07303.
    >> Share

  21. FORTNER RT, Brantley KD, Tworoger SS, Tamimi RM, et al
    Recreational physical activity and breast cancer risk by menopausal status and tumor hormone receptor status: results from the Nurses' Health Studies.
    Breast Cancer Res Treat. 2024 Apr 9. doi: 10.1007/s10549-023-07238.
    >> Share

  22. BRANDAO M, Martins-Branco D, De Angelis C, Vuylsteke P, et al
    Correction: Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium.
    Breast Cancer Res Treat. 2024 Apr 9. doi: 10.1007/s10549-024-07275.
    >> Share

    Cancer Cell

  23. LIN CJ, Jin X, Ma D, Chen C, et al
    Genetic interactions reveal distinct biological and therapeutic implications in breast cancer.
    Cancer Cell. 2024;42:701-719.
    >> Share

    Cancer Lett

  24. WANG J, Fan P, Shen P, Fan C, et al
    XBP1s activates METTL3/METTL14 for ER-phagy and paclitaxel sensitivity regulation in breast cancer.
    Cancer Lett. 2024 Apr 4:216846. doi: 10.1016/j.canlet.2024.216846.
    >> Share

  25. LI K, Lin H, Liu A, Qiu C, et al
    SOD1-high fibroblasts derived exosomal miR-3960 promotes cisplatin resistance in triple-negative breast cancer by suppressing BRSK2-mediated phosphorylation of PIMREG.
    Cancer Lett. 2024;590:216842.
    >> Share

    Cancer Res

  26. ZHENG SM, Feng YC, Zhu Q, Li RQ, et al
    MILIP Binding to tRNAs Promotes Protein Synthesis to Drive Triple-Negative Breast Cancer.
    Cancer Res. 2024 Apr 9:OF1-OF15. doi: 10.1158/0008-5472.CAN-23-3046.
    >> Share

    Clin Breast Cancer

  27. MICHAELS E, Chen N, Nanda R
    The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC).
    Clin Breast Cancer. 2024 Mar 6:S1526-8209(24)00061.
    >> Share

  28. D'ALESSANDRO GS, Munhoz AM, Takeuchi FM, Povedano A, et al
    Is Immediate Breast Reconstruction With a Latissimus Dorsi Myocutaneous Flap Safe for Starting Adjuvant Chemotherapy in Patients With Breast Cancer?
    Clin Breast Cancer. 2024 Mar 10:S1526-8209(24)00076.
    >> Share

    Clin Exp Metastasis

  29. BHAT V, Piaseczny M, Goodale D, Patel U, et al
    Lung-derived soluble factors support stemness/plasticity and metastatic behaviour of breast cancer cells via the FGF2-DACH1 axis.
    Clin Exp Metastasis. 2024 Apr 6. doi: 10.1007/s10585-024-10284.
    >> Share

    Curr Treat Options Oncol

  30. MOLINELLI C, Jacobs F, Nader-Marta G, Borea R, et al
    Ovarian Suppression: Early Menopause and Late Effects.
    Curr Treat Options Oncol. 2024;25:523-542.
    >> Share

    Exp Cell Res

  31. SHOME R, Sen P, Sarkar S, Ghosh SS, et al
    Single-cell transcriptomics reveals the intra-tumoral heterogeneity and SQSTM1/P62 and Wnt/beta-catenin mediated epithelial to mesenchymal transition and stemness of triple-negative breast cancer.
    Exp Cell Res. 2024 Apr 5:114032. doi: 10.1016/j.yexcr.2024.114032.
    >> Share


  32. DEHGHANIAN F, Ghahnavieh LE, Nilchi AN, Khalilian S, et al
    Breast cancer drug resistance: Decoding the roles of Hippo pathway crosstalk.
    Gene. 2024;916:148424.
    >> Share

  33. VOSOOGHI R, Motavalizadehkakhky A, Mansouri A, Mehrzad J, et al
    Investigating the effect of hesperetin on estrogen receptor alpha (ERalpha) expression, phosphorylation and activity in MCF-7 cells.
    Gene. 2024;911:148357.
    >> Share

    Int J Radiat Oncol Biol Phys

  34. LOVING BA, Almahariq MF, Sivapalan S, Levitin R, et al
    Newly Diagnosed Mental Health Disorders in Patients with Breast Cancer Receiving Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2024 Apr 4:S0360-3016(24)00445.
    >> Share

    J Clin Invest

    Surviving without BRCA2: MLH1 gets R-looped in to curtail genomic instability.
    J Clin Invest. 2024;134:e179325.
    >> Share

    J Clin Oncol

  36. RIOS-HOYO A, Cobain E, Huppert LA, Beitsch PD, et al
    Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer.
    J Clin Oncol. 2024 Apr 9:JCO2302614. doi: 10.1200/JCO.23.02614.
    >> Share

    J Natl Cancer Inst

  37. OMOLEYE OJ, Esserman LJ, Olopade OI
    RE: Supplemental magnetic resonance imaging plus mammography compared with magnetic resonance imaging or mammography by extent of breast density.
    J Natl Cancer Inst. 2024;116:627-628.
    >> Share

  38. VILLY MC, Le Ven A, Le Mentec M, Masliah-Planchon J, et al
    Familial uveal melanoma and other tumors in 25 families with monoallelic germline MBD4 variants.
    J Natl Cancer Inst. 2024;116:580-587.
    >> Share


  39. NAROD SA
    Breast Cancer and Pregnancy in Young BRCA Carriers.
    JAMA. 2024;331:1233-1234.
    >> Share

  40. BLONDEAUX E, Partridge AH, Lambertini M
    Breast Cancer and Pregnancy in Young BRCA Carriers-Reply.
    JAMA. 2024;331:1234.
    >> Share


  41. PEREZ-GARCIA JM, Cortes J, Ruiz-Borrego M, Colleoni M, et al
    3-year invasive disease-free survival with chemotherapy de-escalation using an (18)F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
    Lancet. 2024 Apr 3:S0140-6736(24)00054-0. doi: 10.1016/S0140-6736(24)00054.
    >> Share

  42. EARL HM
    Safe de-escalation of chemotherapy in HER2-positive early breast cancer.
    Lancet. 2024 Apr 3:S0140-6736(24)00535-X. doi: 10.1016/S0140-6736(24)00535.
    >> Share

    Lancet Oncol

  43. VAN DER VOORT A, Louis FM, van Ramshorst MS, Kessels R, et al
    MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study.
    Lancet Oncol. 2024 Apr 5:S1470-2045(24)00104.
    >> Share

    Mol Ther Oncol

  44. LIAO Q, Zhang R, Ou Z, Ye Y, et al
    TROP2 is highly expressed in triple-negative breast cancer CTCs and is a potential marker for epithelial mesenchymal CTCs.
    Mol Ther Oncol. 2024;32:200762.
    >> Share

    N Engl J Med

  45. DE BONIFACE J, Filtenborg Tvedskov T, Ryden L, Szulkin R, et al
    Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases.
    N Engl J Med. 2024;390:1163-1175.
    >> Share


  46. ABRAHAM JE, Pinilla K, Dayimu A, Grybowicz L, et al
    The PARTNER trial of neoadjuvant olaparib in triple-negative breast cancer.
    Nature. 2024 Apr 8. doi: 10.1038/s41586-024-07384.
    >> Share

    NPJ Breast Cancer

  47. BAR Y, Keenan JC, Niemierko A, Medford AJ, et al
    Genomic spectrum of actionable alterations in serial cell free DNA (cfDNA) analysis of patients with metastatic breast cancer.
    NPJ Breast Cancer. 2024;10:27.
    >> Share


  48. BOTTONI L, Minetti A, Realini G, Pio E, et al
    NRF2 activation by cysteine as a survival mechanism for triple-negative breast cancer cells.
    Oncogene. 2024 Apr 10. doi: 10.1038/s41388-024-03025.
    >> Share

    PLoS One

    An improved breast cancer classification with hybrid chaotic sand cat and Remora Optimization feature selection algorithm.
    PLoS One. 2024;19:e0300622.
    >> Share

  50. SLOJEWSKA K, Galbarczyk A, Klimek M, Tubek-Krokosz A, et al
    Higher number of steps is related to lower endogenous progesterone but not estradiol levels in women.
    PLoS One. 2024;19:e0299580.
    >> Share

    Radiol Artif Intell

  51. LARSEN M, Olstad CF, Lee CI, Hovda T, et al
    Performance of an AI System for Breast Cancer Detection on Screening Mammograms from BreastScreen Norway.
    Radiol Artif Intell. 2024 Apr 10:e230375. doi: 10.1148/ryai.230375.
    >> Share

    Radiol Imaging Cancer

  52. SPRAGUE BL, Nowak SA, Ahern TP, Herschorn SD, et al
    Long-term Mammography Screening Trends and Predictors of Return to Screening after the COVID-19 Pandemic: Results from a Statewide Registry.
    Radiol Imaging Cancer. 2024;6:e230161.
    >> Share

  53. POLAT DS, Nguyen S, Karbasi P, Hulsey K, et al
    Machine Learning Prediction of Lymph Node Metastasis in Breast Cancer: Performance of a Multi-institutional MRI-based 4D Convolutional Neural Network.
    Radiol Imaging Cancer. 2024;6:e230107.
    >> Share


  54. LIU Y, Sorkhei M, Dembrower K, Azizpour H, et al
    Use of an AI Score Combining Cancer Signs, Masking, and Risk to Select Patients for Supplemental Breast Cancer Screening.
    Radiology. 2024;311:e232535.
    >> Share

  55. KIM MK, Chang JM
    AI-driven Selection of Candidates for Supplemental Breast Cancer Screening.
    Radiology. 2024;311:e240447.
    >> Share

    Semin Oncol

  56. SOBRINI-MORILLO P, Ravot C, Herledan C, Sanchez-Castellano C, et al
    Real-world experience with CDK4-6 inhibition in the old and oldest old with a diagnosis of breast cancer.
    Semin Oncol. 2024 Feb 22:S0093-7754(24)00003.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016